The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disorder characterised by joint inflammation and destruction. Controversy exists regarding the significance and exact role of activated T cells in RA. CTLA4Ig is a soluble fusion protein (cytotoxic T lymphocyte-associated antigen 4 fused to the heavy chain constant region of human IgG1), which represents the first in a new class of agents called costimulation blockers. By blocking the second signal required for optimal T-cell activation, CTLA4Ig has demonstrated efficacy in a variety of spontaneous and induced animal models of autoimmunity. A Phase II clinical study in RA showed CTLA4Ig was efficacious with an acceptable safety profile. These results suggest that activated T cells may be important in RA pathogenesis and that costimulation blockade may be a novel therapeutic approach for this disorder.

[1]  Wei Wei,et al.  New therapeutic approaches for rheumatoid arthritis. , 2005, Assay and drug development technologies.

[2]  R. Strieter,et al.  Chemokines in rheumatoid arthritis , 2004, Springer Seminars in Immunopathology.

[3]  P. Bendtsen,et al.  Change and status in quality of life in patients with rheumatoid arthritis , 1992, Quality of Life Research.

[4]  M. Weisman.  What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. , 2002, The Journal of rheumatology. Supplement.

[5]  Stanley B. Cohen,et al.  Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. , 2002, Arthritis and rheumatism.

[6]  E. Clair,et al.  Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases , 2002 .

[7]  I. McInnes,et al.  Novel pathways that regulate tumor necrosis factor-alpha production in rheumatoid arthritis. , 2002, Current opinion in rheumatology.

[8]  A. Silman,et al.  Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. , 2002, Arthritis and rheumatism.

[9]  F. Breedveld.  Current and future management approaches for rheumatoid arthritis , 2002, Arthritis research.

[10]  T. Uede,et al.  Prevention of Acute Lung Allograft Rejection in Rat by CTLA4Ig , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  T. Martin,et al.  Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis , 2002 .

[12]  M. Boothby,et al.  Constitutive expression of BCL-X(L) in the T lineage attenuates collagen-induced arthritis in Bcl-X(L) transgenic mice. , 2002, Arthritis and rheumatism.

[13]  E. S. St. Clair.  Tides of inflammation: impact of biologics. , 2002, The Journal of rheumatology. Supplement.

[14]  L. Joosten,et al.  IL-1-Independent Role of IL-17 in Synovial Inflammation and Joint Destruction During Collagen-Induced Arthritis1 , 2001, The Journal of Immunology.

[15]  N. Kamatani,et al.  Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. , 2001, Arthritis and rheumatism.

[16]  G. Panayi,et al.  PATHOGENESIS OF RHEUMATOID ARTHRITIS , 2001 .

[17]  I. McInnes.  Rheumatoid arthritis. From bench to bedside. , 2001, Rheumatic diseases clinics of North America.

[18]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[19]  D. Wofsy,et al.  Cutting Edge: Reversal of Murine Lupus Nephritis with CTLA4Ig and Cyclophosphamide1 , 2001, The Journal of Immunology.

[20]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[21]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[22]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[23]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[24]  T. Martin,et al.  Tumor Necrosis Factor (cid:97) Stimulates Osteoclast Differentiation by a Mechanism Independent of the ODF/RANKL–RANK Interaction , 2022 .

[25]  C. Weyand,et al.  The role of T cells in rheumatoid arthritis. , 2000, Archivum immunologiae et therapiae experimentalis.

[26]  M. Lebwohl,et al.  CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. , 1999, The Journal of clinical investigation.

[27]  M. Sayegh.  Finally, CTLA4Ig graduates to the clinic. , 1999, The Journal of clinical investigation.

[28]  P. Klimiuk,et al.  Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. , 1999, Clinical immunology.

[29]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[30]  P. Linsley,et al.  Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. , 1997, Journal of immunology.

[31]  M. Feldmann,et al.  Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2 , 1996, European journal of immunology.

[32]  F. Breedveld,et al.  Biologic agents for the treatment of rheumatoid arthritis. , 1996, Rheumatic diseases clinics of North America.

[33]  R. Strieter,et al.  The role of chemokines in inflammatory joint disease , 1996, Journal of leukocyte biology.

[34]  E. Keystone,et al.  Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)‐1β production by synovial T cells , 1995, Clinical and experimental immunology.

[35]  J. Bluestone,et al.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse , 1995, The Journal of experimental medicine.

[36]  P. Albert,et al.  Role of B7:CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. , 1995, Journal of immunology.

[37]  J. Gribben,et al.  Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. , 1994, Science.

[38]  J. Gribben,et al.  CD2 is involved in maintenance and reversal of human alloantigen- specific clonal anergy , 1994, The Journal of experimental medicine.

[39]  P. Linsley,et al.  Treatment of murine lupus with CTLA4Ig. , 1994, Science.

[40]  P. Linsley,et al.  Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.

[41]  K. Takagishi,et al.  Experimental arthritis induced by continuous infusion of IL‐8 into rabbit knee joints , 1994, Clinical and experimental immunology.

[42]  G. Passeri,et al.  Interleukin-11: a new cytokine critical for osteoclast development. , 1994, The Journal of clinical investigation.

[43]  P. Linsley,et al.  Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. , 1994, Journal of immunology.

[44]  M. Burdick,et al.  Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. , 1994, The Journal of clinical investigation.

[45]  Y. Nagai,et al.  The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells , 1993, Clinical and experimental immunology.

[46]  T. Wyss-Coray,et al.  The B7 adhesion molecule is expressed on activated human T cells: Functional involvement in T‐T cell interactions , 1993, European journal of immunology.

[47]  J. Gribben,et al.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  D. Willoughby,et al.  Cartilage degradation by polymorphonuclear leucocytes: in vitro assessment of the pathogenic mechanisms. , 1993, Annals of the rheumatic diseases.

[49]  C Anasetti,et al.  Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 , 1993, The Journal of experimental medicine.

[50]  L. Moreland,et al.  New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. , 1993, The American journal of the medical sciences.

[51]  P. Linsley,et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes , 1992, The Journal of experimental medicine.

[52]  M. Burdick,et al.  Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. , 1992, The Journal of clinical investigation.

[53]  I. Chikanza,et al.  Treatment of Rheumatoid Arthritis with Single Dose or Weekly Pulses of Chimaeric Anti‐CD4 Monoclonal Antibody , 1992, Scandinavian journal of immunology.

[54]  R. Steinman,et al.  The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. , 1992, The Journal of clinical investigation.

[55]  R. Chang,et al.  The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. , 1992, Arthritis and rheumatism.

[56]  J. Lanchbury.  The HLA association with rheumatoid arthritis. , 1992, Clinical and experimental rheumatology.

[57]  J. Allison,et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones , 1992, Nature.

[58]  M. Jenkins,et al.  CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. , 1991, Journal of immunology.

[59]  K. Matsushima,et al.  Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. , 1991, Lymphokine and cytokine research.

[60]  C. Menkes,et al.  Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. , 1991, Journal of autoimmunity.

[61]  D. Wendling,et al.  Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. , 1991, The Journal of rheumatology.

[62]  E. Clark,et al.  The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells , 1991, The Journal of experimental medicine.

[63]  P. Linsley,et al.  Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.

[64]  J. Van Snick.  Interleukin-6: an overview. , 1990, Annual review of immunology.

[65]  R. Schwartz,et al.  Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. , 1989, Annual review of immunology.

[66]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[67]  P. Gertman,et al.  Health status in chronic disease: a comparative study of rheumatoid arthritis. , 1983, The Journal of rheumatology.

[68]  K. Lafferty,et al.  Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. , 1983, Annual review of immunology.